Open access
Open access
Powered by Google Translator Translator

Patients with lymphoma receiving B-Cell–depleting therapies may be at greater risk for persistent COVID-19 infection

9 Feb, 2021 | 01:14h | UTC

Patients With Lymphoma Receiving B-Cell–Depleting Therapies May Be at Greater Risk for Persistent COVID-19 Infection – The ASCO Post

Related: Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection – The ASCO Post

See also: Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients — Plus: Active chemo treatment may not be a COVID risk factor – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.